Publications

Access to the model

The IQVIA CORE Diabetes Model team and other users regularly publish articles based on the IQVIA CORE Diabetes Model and presents in conferences such as ISPOR, the European Diabetes Association Annual Meeting or the American Diabetes Association Congress.

Articles

Titles / Authors	Journal	Year	Read it
The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes (Fonda S, Graham C, Munakata J, Powers J, Price D, Vigersky R)	Journal of diabetes science and technology	2016
A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus (Henriksson M, Jindal R, Sternhufvud C, Bergenheim K, Sörstadius E, Willis M.)	Pharmacoeconomics	2016
Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand (Permsuwan U, Chaiyakunapruk N, Dilokthornsakul P, Thavorn K, Saokaew S)	Applied Health Economics and Health Policy	2016
Development of an economic evaluation of diagnostic strategies: the case of monogenic diabetes (Peters J, Anderson R, Hye C)	BMJ Open	2016
Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective (Roze S, Smith-Palmer J, Valentine W, Cook M, Jethwa M, de Portud S, Pickup J)	Journal of Medical Ethics	2016
Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands. (Roze S, Duteil E, Smith-Palmer J, de Portu S, Valentine W, de Brouwer B, Reznik Y, de Valk HW.)	J Med Econ	2016
Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France. (Roze S, Smith-Palmer J, Valentine W, Payet V, de Portu S, Papo N, Cucherat M, Hanaire H.)	Diabetes Technol Ther	2016
Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective.  (Roze S, Smith-Palmer J, Valentine WJ, Cook M, Jethwa M, de Portu S, Pickup JC.)	J Med Econ	2016
Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.  (Roussel R, Martinez L, Vandebrouck T, Douik H, Emiel P, Guery M, Hunt B, Valentine WJ. )	J Med Econ	2016
Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives (Deng W, Qui S, Yang G, Chen B)	Journal of Therapeutics and Clinical Risk Management	2015
Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluation. (Evans M, McEwan P, Foos V.)	Journal of Medical Economics	2015
Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy (Gordon J, Evans M, Puelles J, McEwan P)	Diabetes Therapy	2015
Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway (Huetson P,  Palmer J, Levorsen J, Fournier M, Germe M, McLeod E)	Journal of Medical Economics	2015
A Health Economic Evaluation of the Edge Study Using the Ims Core Diabetes Model (Lamotte M, Foos V, McEwan P, Paldanius P)	Value in Health	2015
Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK. (Valentine WJ, Curtis BH, Pollock RF, Van Brunt K, Paczkowski R, Brändle M, Boye KS, Kendall DM.)	Diabetes Res Clin Pract.	2015
Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in type 1 diabetes: a systematic review. (Roze S, Smith-Palmer J, Valentine W, de Portu S, Nørgaard K, Pickup JC. )	Diabetic Medicine	2015
Cost-effectiveness of switching from biphasic human insulin (BHI) to biphasic insulin aspart 30 (BIAsp-30) in type 2 diabetes patients with suboptimal glycaemic control in Singapore. (Goh SY, Tan SC, Lim LC, Chua B, Hunt B.)	Journal of Diabetology	2015
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico. (Hunt B, Aguilar Garza JL, Enríquez Vázquez CJ, Jain P, Valentine WJ.)	Value in Health Regional Issues	2015
Health-economic analysis of real-time continuous glucose monitoring in people with type 1 diabetes.  (Roze S, Saunders R, Brandt AS, de Portu S, Papo NL, Jendle J.)	Diabetic Medicine	2015
Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin.  (Pérez A, Mezquita Raya P, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ.)	Diabetes Therapy	2015
Validation of the IMS CORE Diabetes Model. (McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D.)	Value in Health	2014
Improving quality of care in people with Type 2 diabetes through the Associazione Medici Diabetologi-annals initiative: a long-term cost-effectiveness analysis. (Giorda CB, Nicolucci A, Pellegrini F, Kristiansen CK, Hunt B, Valentine WJ, Vespasiani G.)	Diabetic Medicine	2014
Cost Effectiveness Analysis of Flash Glucose Monitoring for Type 2 Diabetes Patients Receiving Insulin Treatment In The Uk (Li H, Bilir S, Donga, Samiian P, Munakata J)	Value in Health	2014
The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain. (Fonseca T, Clegg J, Caputo G, Norrbacka K, Dilla T, Alvarez M.)	J Med Econ	2013
Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. (Ericsson Å, Pollock RF, Hunt B, Valentine WJ.)	Journal of Medical Economics	2013
Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin.  (Mezquita Raya P, Pérez A, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ. )	Diabetes Therapy	2013
Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK. (Pollock RF, Muduma G, Valentine WJ. )	Diabetes, Obesity and Metabolism	2013
Correlating Cost Effectiveness Output with Patient Level Data Input Via the IMS Core Diabetes Model (CDM) (Lamotte M, Foos V, McEwan P, Palmer J)	Value in Health	2013
Validation Of The Ukpds Outcomes Equations Using The Cardiff Type-2 Diabetes Model (McEwan P)	Value in Health	2013
Therapy Escalation Thresholds and the Potential for Biased Cost Effectiveness Analysis When Failing to Sample Baseline HbA1c in Type 2 Diabetes (McEwan P, Foos V, Palmer J, Lamotte M, Grant D)	Value in Health	2013
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. (Davies MJ, Chubb BD, Smith IC, Valentine WJ)	Diabet Med	2012
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. (Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA)		2012
Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. (Kamble S, Schulman KA, Reed SD)	Value Health	2012
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.  (Lee WC, Samyshkin Y, Langer J, Palmer JL)	J Med Econ	2012
A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. (Pollock RF, Curtis BH, Valentine WJ)	J Med Econ	2012
A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin.  (Pollock RF, Curtis BH, Smith-Palmer J, Valentine WJ)	Adv Ther	2012
Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.  (Samyshkin Y, Guillermin AL, Best JH, Brunell SC, Lloyd A)	J Med Econ	2012
Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.  (Smith-Palmer J, Fajardo-Montanana C, Pollock RF, Ericsson A, Valentine WJ)	J Med Econ	2012
Cost-effectiveness of biphasic insulin aspart 30 vs. human premix insulin in type 2 diabetes from the payer's perspective in Bulgaria. (Valov V, Palmer J, Czech M, Savova A, Petrova G)	Biotechnology & Biotechnological Equipment	2012
Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study. (Yang L, Christensen T, Sun F, Chang J)	Value Health	2012
Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK (Palmer JL, Timlin L, Wilson B, Bruhn D, Boye KS, et al)	J Med Econ	2011
Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. (Goodall G, Costi M, Timlin L, Reviriego J, Sacristan JA, Smith-Palmer J, et al)	Endocrinol Nutr	2011
Modelling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. (Guillermin AL, Samyshkin Y, Wright D, Nguyen T, Villeneuve J)		2011
Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. (Lee WC, Conner C, Hammer M)	Curr Med Res Opin	2011
Economic analysis of the implementation of guidelines for type 2 diabetes control developed by Diabetes Poland: what increase in costs is justified by clinical results? (Szmurlo D, Schubert A, Kostrzewska K, Rys P, Skrzekowska-Baran I)	Pol Arch Med Wewn	2011
Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden.  (Valentine WJ, Aagren M, Haglund M, Ericsson A, Gschwend MH)	Scand J Public Health	2011
Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. (Valentine WJ, Palmer AJ, Lammert M, Langer J, Brandle M)	Clin Ther	2011
Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. (Lee WC, Conner C, Hammer M)	Clin Ther	2010
Cost-effectiveness of continuous subcutaneous insulin infusion therapy for type 1 diabetes.  (Norgaard K, Sohlberg A, Goodall G)	Ugeskr Laeger	2010
Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting.  (Palmer JL, Knudsen MS, Aagren M, Thomsen TL)	J Med Econ	2010
Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China.  (Palmer JL, Beaudet A, White J, Plun-Favreau J, Smith-Palmer J)	Adv Ther	2010
Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents. (Pollock RF, Valentine WJ, Goodall G, Brandle M)	Swiss Med Wkly	2010
Anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: a hypothetical modelling analysis.  (Smith-Palmer J, Curtis BH, Boye KS, Goodall G, Pillemer SR)	Diabet Med	2010
Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US. (Tunis SL, Minshall ME)	Curr Med Res Opin	2010
Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.  (Tunis SL, Willis WD, Foos V)	Curr Med Res Opin	2010
Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada. (Tunis SL, Sauriol L, Minshall ME)	Appl Health Econ Health Policy	2010
Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. (Brandle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ)	Int J Clin Pharmacol Ther	2009
Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting.  (Brandle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WJ)	Swiss Med Wkly	2009
Cost-effectiveness of insulin analogues for diabetes mellitus.  (Cameron CG, Bennett HA)	CMAJ	2009
Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences. (Fonseca VA, Smith H, Kuhadiya N, Leger SM, Yau CL, Reynolds K, et al)	Diabetes Care	2009
The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study.  (Goodall G, Sarpong EM, Hayes C, Valentine WJ)	BMC Endocr Disord	2009
Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. (Gschwend MH, Aagren M, Valentine WJ)	J Med Econ	2009
Cost-effectiveness of Roux-en-Y gastric bypass in type 2 diabetes patients. (Ikramuddin S, Klingman D, Swan T, Minshall ME)	Am J Manag Care	2009
Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.  (Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ)	Value Health	2009
Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. (Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G)	Diabetes Obes Metab	2009
An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK. (Pratoomsoot C, Smith HT, Kalsekar A, Boye KS, Arellano J, Valentine WJ)	Diabet Med	2009
Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. (Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ)	Cost Eff Resour Alloc	2009
Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. (St Charles ME, Sadri H, Minshall ME, Tunis SL)	Clin Ther	2009
A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective. (St Charles M, Lynch P, Graham C, Minshall ME)	Value Health	2009
A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.  (St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL)	Curr Med Res Opin	2009
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.  (Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L)	Cardiovasc Diabetol	2009
A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.  (Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L)	Pharmacotherapy	2009
A cost-effectiveness analysis to illustrate the impact of cost definitions on results, interpretations and comparability of pharmacoeconomic studies in the US. (Tunis SL)	Pharmacoeconomics	2009
Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modelling analysis.  (Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, et al)	Curr Med Res Opin	2009
Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive. (Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C)	Value Health	2009
Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.  (Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, et al)	J Med Econ	2008
Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.  (Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, Roze S, et al)	Value Health	2008
Complication reducing effect of the information technology-based diabetes management system on subjects with type 2 diabetes. (Cho JH, Lee JH, Oh JA, Kang MJ, Choi YH, Kwon HS, et al)	J Diabetes Sci Technol	2008
Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.  (Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, et al)	Int J Clin Pract	2008
Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. (Minshall ME, Oglesby AK, Wintle ME, Valentine WJ, Roze S, Palmer AJ)	Value Health	2008
Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark. (Palmer AJ, Lammert M, Hermansen K)	Ugeskr Laeger	2008
Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. (Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, et al)	Curr Med Res Opin	2008
Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.  (Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, et al)	Adv Ther	2008
Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance-«) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting.  (Ray JA, Huet D, Valentine WJ, Palmer AJ, Cugnardey N, Renaudin C)	The British Journal of Diabetes & Vascular Disease	2008
Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states.  (Tunis SL, Minshall ME)	Am J Manag Care	2008
The impact of clinical trial design on cost-effectiveness analyses: illustration from a published study of the one-touch ultrasmart blood glucose meter for insulin-using diabetes patients. (Tunis SL, Minshall ME)	Diabetes Technol Ther	2008
Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.  (Tunis SL, Minshall ME, St CM, Pandya BJ, Baran RW)	Curr Med Res Opin	2008
Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.  (Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K)	Adv Ther	2008
Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. (Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ)	Pharmacoeconomics	2007
Cost-effectiveness of diabetes case management for low-income populations. (Gilmer TP, Roze S, Valentine WJ, Emy-Albrecht K, Ray JA, Cobden D, et al)	Health Serv Res	2007
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. (Palmer AJ, Valentine WJ, Ray JA, Foos V, Lurati F, Smith I, et al)	Curr Med Res Opin	2007
Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain. (Pinol C, Roze S, Valentine W, Evers T)	Gac Sanit	2007
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. (Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, et al)	Curr Med Res Opin	2007
Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. (Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, et al)	Diabetes Obes Metab	2007
Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modelling study of cost-effectiveness in the United States. (Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer A)	Adv Ther	2007
PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. (Valentine WJ, Bottomley JM, Palmer AJ, Brandle M, Foos V, Williams R, et al)	Diabet Med	2007
Cost-utility analysis of insulin pumps compared to multiple daily doses of insulin in patients with type 1 diabetes mellitus in Spain.  (Conget D, I, Serrano CD, Rodriguez Barrios JM, Levy M, I, Castell AC, Roze S)	Rev Esp Salud Publica	2006
Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes.  (Palmer AJ, Dinneen S, Gavin JR, III, Gray A, Herman WH, Karter AJ)	Curr Med Res Opin	2006
Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting. (Roze S, Valentine WJ, Evers T, Palmer AJ)	Curr Med Res Opin	2006
Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. (Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, et al)	Adv Ther	2006
Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets.  (Valentine WJ, Palmer AJ, Nicklasson L, Cobden D, Roze S)	Int J Clin Pract	2006
Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.  (Watkins JB, Minshall ME, Sullivan SD)	J Manag Care Pharm	2006
Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. (Minshall ME, Roze S, Palmer AJ, Valentine WJ, Foos V, Ray J, et al)	Clin Ther	2005
Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. (Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ)	Diabet Med	2005
Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting.  (Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S)	Curr Med Res Opin	2005
The CORE Diabetes Model.  (Brandle M, Herman WH)	Curr Med Res Opin	2004
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. (Palmer AJ, Roze S, Lammert M, Valentine WJ, Minshall ME, Nicklasson L, et al)	Curr Med Res Opin	2004
Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model.  (Palmer AJ, Roze S, Valentine WJ, Minshall ME, Hayes C, Oglesby A, et al)	Curr Med Res Opin	2004
Validation of the CORE Diabetes Model against epidemiological and clinical studies. (Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al)	Curr Med Res Opin	2004
What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.  (Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Oglesby A, et al)	Curr Med Res Opin	2004
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. (Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al)	Curr Med Res Opin	2004
Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy. (Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Nicklasson L, et al)	Curr Med Res Opin	2004
Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. (Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU)	Curr Med Res Opin	2004

Conference presentations

Titles / Authors	Document type	Read it
ISPOR 18th Annual European Congress, Milan, 7-11 November 2015
Reduction of Complications and Associated Costs for Type 2 Diabetic Patients Using Continuous Subcutaneous Insulin Infusion In The UK (Roze S , Duteil E, Hallas N, de Portu S)	Poster
Health-economic analysis of the use of sensor-augmented pump (SAP) therapy in the Netherlands compared to insulin pump therapy alone (CSII), in type 2 diabetic patients (Roze S , Duteil E, Hallas N, de Portu S)	Poster
Contrasting model predicted life expectancy in patients with type 2 diabetes across diferrent mortality risk prediction models versus data from the Canadian chronic disease surveillance system (Foos V, Lamotte M, McEwan P)	Poster
Validating approaches to modelling end-stage renal disease using the IMS Core Diabetes Model (Foos V, Lamotte M, McEwan P)	Poster
EASD 51st annual meeting, Stockholm, 14-18 September 2015
Contrasting eight cardiovascular risk equations for use in type 2 diabetes cohorts using the CORE Diabetes Model (Lamotte M, Foos V, McEwan P)	Abstract
ISPOR 20th Annual International Meeting , Philadelphia, 18-20 May 2015
Contrasting The Relative Risk Reduction Of Cardiovascular Events In The Core Diabetes Model Associated With Single Risk Factor Changes Across Alternative Risk Engines: Ukpds68, Ukpds82 And Swedish National Diabetes Registry Equations (Foos V, Lamotte M, McEwan P)	Poster
Assessing the relative contribution to changes in quality adjusted life expectancy associated with HbA1c, weight and hypoglycaemia across multiple risk equations with the CORE Diabetes Model. (McEwan P, Evans M, Lamotte M, Foos V)	Poster
Contrasting cost effectiveness results derived from contemporary sets of alternative risk equations in type 2 diabetes (Volker Foos, Mark Lamotte, Phil McEwan)	Poster
Validating the ukpds 82 risk equations to contemporary outcomes studies in type 2 diabetes (Grant D, Foos V, McEwan P )	Poster
ISPOR 17th Annual European Congress, Amsterdam, 8-12 November 2014
Assessing the relationship between improved life expectancy due to better cardiovascular risk factor management and the likelihood of microvascular complications in type 2 diabetes mellitus (P. McEwan, D. Grant and V. Foos)	Poster
Progression of Physiological Measurements Over Time in Type 1 Diabetes Mellitus Patients in France (A. Beaudet, R. Ong, A. Solomiac, N. Grandfils)	Poster
Burden of Non-adherence to Type 1 Diabetes Mellitus Therapeutic Guidelines in France (A. Beaudet, R. Ong, X. Ansolabehere, P. Le Jeunne)	Poster
All cause mortality validation of the IMS CORE diabetes model against predictions of the Charlson Comorbidity Index (V. Foos, P. McEwan, M. Lamotte and D. Grant)	Poster
Impact of single risk factor changes on long term outcomes and cost in a type 2 diabetes modeling study contrasting projections with UKPDS 68 versus UKPDS 82 risk equations (V. Foos, P. McEwan and D. Grant)	Poster
Quantifying nonlinear effects in stochastic Markov simulation using UKPDS 68 and UKPDS 82 equations in type 2 diabetes modeling analysis with the IMS CORE Diabetes Model (CDM) (P. McEwan, D. Grant, M. Lamotte and V. Foos)	Poster
Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Portugal (Troelsgaard A, Knudsen M, Maia-Lopes S, Luz M, Hemels M)	Poster
Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Slovakia (Troelsgaard A, Pitcher A, Binder R, Stetka R, Lovato E, Ondrusova M)	Poster
The Cost-Effectiveness of Canagliflozin Compared With Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sulphonylurea in France (Troelsgaard A, Pitcher A, Lloyd A, Granados D, Hemels M)	Poster
Health Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Czech Republic (Troelsgaard A, Pitcher A, Vesela S, Lovato E, Hemels M)	Poster
ISPOR 19th Annual International Meeting, May 31- June 4, 2014, Montréal, Canada
Comparing simulation run time requirements to achieve stabilized absolute and incremental costs effectiveness results in probabilistic vs. deterministic modeling analysis (V. Foos, P. McEwan and D. Grant)	Poster
Contrasting cost effectiveness results derived from the UKPDS 68 and 82 risk equations in Type 2 diabetes (P. McEwan, V. Foos, and D. Grant)	Poster
Illustrating the relationship between the number of hypoglycemic events, event rate reduction and the impact on estimates of quality of life improvement in health economic studies (V. Foos, P. McEwan and D. Grant)	Poster
Validating the UKDS 82 risk equations to contemporary outcomes studies in type 2 diabetes (D. Grant, V. Foos and P. McEwan)	Poster
Assessing simulation run time requirements to achieve stabilized absolute and incremental cost effectiveness results in type 2 diabetes: A study using the Core Diabetes model (Foos V, Grant D, McEwan P)	Poster
The Cost-Effectiveness Evaluation of Canagliflozin Versus Dapagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy in Spain (Nielsen A, Pitcher A, Lovato E, Schubert A, Hemels M, Neslusan C, González B)	Poster
ISPOR 16th Annual European Congress, 2-6 November 2013, Dublin, Ireland
Assessing the significance of HbA1c durability in cost effectiveness analysis of 2nd line oral therapies in the management of type 2 diabetes. (P. McEwan, V. Foos, A. Lloyd, J. Palmer, M. Lamotte and D. Grant)	Poster
Review of Cost of Diabetes Complications in Four European Countries. (A. Beaudet, E. Grabbi, F. Maurel, M. Ramos, A. Lebioda)	Poster
Therapy escalation thresholds and the potential for biased cost effectiveness analysis when failing to sample baseline HbA1c in type 2 diabetes. (P. McEwan, V. Foos, A. Lloyd, J. Palmer, M. Lamotte and D. Grant)	Poster
Correlating cost-effectiveness output with patient-level data input via the IMS CORE Diabetes Model (CDM). (P. McEwan, V. Foos, J. Palmer, M. Lamotte and D. Grant)	Poster
The role of simulation modelling in planning long-term clinical trials in type 2 diabetes. (P. McEwan, V. Foos, A. Lloyd, J. Palmer, M. Lamotte and D. Grant)	Poster
EASD 49th Annual Meeting, 23-27 September 2013, Barcelona, Spain
Are we failing to capture the relationship between body mass index and cardiovascular disease and mortality in subjects with type 2 diabetes? (D. Grant, P. McEwan, V. Foos, J. Palmer and A. Lloyd)	Poster
Defining the health economic value of avoiding weight gain and hypoglycaemia in type 2 diabetes Mellitus. (A. Lloyd, V. Foos, P. McEwan, D. Grant, M. Lamotte, J. Palmer)	Poster
ADA 73rd Scientific Sessions, 21-25 June 2013, Chicago, IL, USA
Do existing risk equations fail to adequately account for the relationship between body mass index and mortality in subjects with type 2 diabetes? (P. McEwan, V. Foos, D. Grant, J. Palmer, M. Lamotte and A. Lloyd)	Poster
Assessing the Consistency of Absolute Cardiovascular Risk Prediction and Relative Risk Reduction in Type 2 Diabetes Mellitus. (P. McEwan, M. Lamotte, D. Grant, J. Palmer, A. Lloyd and V. Foos)	Poster
ISPOR 18th Annual International Meeting, 18-22 May, 2013 New Orleans, LA, USA
Drivers of cost-effectiveness in type-2 diabetes mellitus. (McEwan P, Foos V, Grant D, Lamotte M, Palmer JL, Lloyd A)	Podium presentation, Poster
Do existing risk equations fail to adequately account for the relationship between body mass index and mortality in subjects with type-2 diabetes? (McEwan P, Foos V, Grant D, Palmer JL, Lamotte M, Lloyd A)	Poster
Assessing the consistency of absolute cardiovascular risk prediction and relative risk reduction in type-2 diabetes mellitus. (McEwan P; Lamotte M; Grant D; Palmer JL; Lloyd A, Foos V)	Poster
The cost and productivity consequences of non-severe hypoglycaemic episodes (nshe) in patients treated with sulfonylurea or dpp4 dual combination oral therapy. (Foos V, McEwan P, Grant D, Palmer JL, Lamotte M, Lloyd A)	Poster
ISPOR 15th European Congress, 3-7 November 2012, Berlin, Germany
Random number generators in Monte Carlo simulation. (McEwan P, Foos V, Chraibi M, Lloyd A, Palmer JL, Lamotte M, Grant D)	Poster
Minimum run-time requirements to reduce Monte Carlo error in stochastic simulations. (Foos V, McEwan P, Lloyd A, Palmer JL, Lamotte M, Grant D)	Poster
Systematic literature review of utility values associated with Type 2 Diabetes-related complications. (Beaudet A, Clegg JP, Lloyd A)	Poster
48th EASD Annual Meeting, 1-5 October 2012, Berlin, Germany
Assessing the relationship between the effect of glycemic control and avoided symptomatic hypoglycemia on quality of life in the management of type 2 diabetes. (Foos V, McEwan P, Lloyd A, Palmer JL, Lamotte M, Grant D)	Poster
ISPOR 5th Asia-Pacific Conference, 2-4 September, 2012, Taipei, Taiwan
Direct medical costs of Diabetes Mellitus in China: Annual cost of illness and long-term projections using a validated diabetes model. (Palmer JL, Caputo J, Foos V, Grant D, Lamotte M, Lloyd A, McEwan P)	Poster
72nd Scientific Sessions, American Diabetes Association, 8-12 June, 2012, Philadelphia, PA
Long-Term Validation of the IMS CORE Diabetes Model in Type 1 and Type 2 Diabetes. (Grant D, Foos V , Palmer J, Lloyd A, Evans M, Mcewan P)	Poster
The Cost and Productivity Consequences of Non-Severe Hypoglycaemic Episodes (NSHE) in Patients Receiving Sulfonylurea or DPP4 Dual Combination Oral Therapy. (McEwan P, Evans M, Foos V, Lloyd A, Grant D)	Poster
Validation and Evaluation of the Risk-To-Benefit Ratio of Glucose Lowering Therapies in High Cardiovascular Risk Type 2 Diabetes Patients; Projections using the IMS CORE Diabetes Model. (Foos V, Freemantle N, Palmer J, Grant D, Lloyd A, Evans M, Mcewan P)	Oral presentation
Cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes (T2DM). (Fonda SJ, Graham C, Samyshkin Y, Munakata J, Powers J, Vigersky RA)	Poster
The Mount Hood 2012 Challenge, 7-8 June, 2012, Baltimore Maryland, USA
Minimum run-time requirements to reduce Monte Carlo error in stochastic simulations. (Volker Foos, Phil McEwan, Adam Lloyd, James Palmer, Mark Lamotte and David Grant)	Oral presentation
ISPOR 17th Annual International Meeting. 2-6 June, 2012 Washington, DC, USA
Long-term clinical and economic benefit associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a Core Diabetes Model study. (Lee WC, Samyshkin Y, Langer J, Palmer J)	Poster
ISPOR 14th Annual European Congress, 5-8 November 2011, Madrid, Spain
Projected cost-effectiveness of exenatide once weekly versus exenatide BID for the treatment of type 2 diabetes in the UK. (Wilson BP, Beaudet A, Caputo J, Timlin L)	Poster
Projected long-term clinical and economic outcomes of exenatide once weekly versus sitagliptin for the treatment of type 2 diabetes in the UK. (Beaudet A, Wilson BP, Caputo J, Timlin L)	Poster
Cost-effectiveness of transferring Type-2 Diabetic patients from Neutral Protamine Hagedorn (NPH) To Detemir in Portugal settings. (Carvalho D, Lindner L, Kozarzewski M)	Poster
47th EASD Annual Meeting, 12-16 September 2011, Lisbon, Portugal
Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta-analysis studies. (Foos V, Lloyd A, Freemantle N, Grant D, Herman W)	Oral presentation
Estimating the impact of different methods of utility assessment on the value of interventions in Type 2 diabetes, Oral presentation. (Lloyd A, Foos V, Donatti C, Grant D, Herman W)	Oral presentation
Duration of time off paid employment associated with diabetes-related complications. (Beaudet A, Myrén K-J, Grant D, Lloyd A)	Poster
ISPOR 13th Annual European Congress, 6-9 November 2010, Prague, Czech Republic
Cost-effectiveness of Exenatide Versus Insulin Glargine and Versus Biphasic Insulin Aspart for the Treatment of Type 2 Diabetes in Portugal: A Long-term Health Economic Analysis. (Palmer JL, Pinto CG, Duarte R, Miguel LS, Gregor Z)	Poster
Long-term clinical outcomes of Exenatide once-weekly versus Insulin Glargine for the treatment of Type 2 Diabetes projected using the Core Diabetes Model. (Timlin L, Beaudet A, Wilson B, Bruhn D, Boye KS, Palmer JL, Lloyd A)	Poster
Long-Term cost-consequence analysis of Exenatide once weekly versus Sitagliptin or Pioglitazone in Type 2 Diabetes patients in the United States. (Aledort Gaebler J, Samyshkin Y, Guillermin ALG, Lloyd A)	Poster
ISPOR 4th Asia-Pacific Conference, 5-7 September 2010, Hilton Phuket, Phuket, Thailand
Clinical and cost effectiveness of biphasic insulin aspart 30 once or twice daily versus insulin glargine in type 2 diabetes mellitus: a modeling analysis in the Chinese setting. (Palmer JL, Beaudet A, White,J, Plun-Favreau J,Smith-Palmer J)	Poster
70th Scientific Sessions Abstract Book, 2010
Starting an insulin therapy with glargine leads to lower long-term treatment costs compared to detemir in German type-2-diabetics: Results of a model approach. (Pfohl M, Dippel F-W, Reichelt A, Kostev K, Fuchs S, Kotowa W)	Abstract